Attributes | Values |
---|
rdf:type
| |
Description
| - A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the predicted strain coverage in Europe. MATS (Meningococcal antigen typing system) analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future.
- A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the predicted strain coverage in Europe. MATS (Meningococcal antigen typing system) analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future. (en)
|
Title
| - Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment (en)
|
skos:prefLabel
| - Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment (en)
|
skos:notation
| - RIV/75010330:_____/13:00010108!RIV14-MZ0-75010330
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/75010330:_____/13:00010108
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Neisseria meningitidis; vaccination; vaccine 4CMenB; surveillance; antibodies; randomized controlled trial (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Lancet infectious diseases
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Křížová, Pavla
- Musílek, Martin
- Caugant, D. A.
- Frosch, M.
- Taha, M. K.
- Claus, H.
- Vogel, U.
- Abad, R.
- Borrow, R.
- Deghmane, A. E.
- Findlow, J.
- Vazquez, J. A
- Bambini, S.
- Boccadifuoco, G.
- Carannante, A.
- Comanducci, M.
- Donnelly, J. J.
- Fazio, C.
- Frosi, G.
- Gilchrist, S.
- Giuliani, M. M.
- Hong, E.
- Ledroit, M.
- Lovaglio, P. G.
- Lucidarme, J.
- Medini, D.
- Muzzi, A.
- Oksnes, J.
- Orlandi, L.
- Pizza, M.
- Rappuoli, R.
- Rigat, F.
- Serruto, D.
- Stefanelli, P.
- Stella, M.
- Thompson, D.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| - 10.1016/S1473-3099(13)70006-9
|